All News

Found 3,314 articles

• ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

  1/4/2023

  ImmunoGen, Inc. today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.

• Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

  1/4/2023

  Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.

• ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT.

• ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload

  1/3/2023

  ProfoundBio announced that 1) dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), and 2) the company received clearance from the U.S. Food and Drug Administration (FDA) to initiate the Phase 1 clinical trial evaluating PRO1160.

• Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

  1/3/2023

  Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692) today announced an antibody collaboration, assignment and exclusive license agreement.

• ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

  1/3/2023

  ADC Therapeutics SA announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will serve on the Company’s executive leadership team.

• Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 23, 2022

  12/23/2022

  Pyxis Oncology, Inc. reported on December 23, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 52,560 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 65,701 shares of Pyxis Oncology’s common stock to five newly hired employees.

• LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

  12/23/2022

  LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform.

• 

  Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal

  12/22/2022

  Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.

• CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

  12/22/2022

  CytomX Therapeutics, Inc. announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets.

• Eisai Initiates BLA Submission of Data for Lecanemab in China

  12/22/2022

  Eisai Co., Ltd. and Biogen Inc. announced that Eisai has initiated submission of data for Biologics License Application to the National Medical Products Administration of China for lecanemab, an investigational anti-amyloid beta protofibril antibody.

• Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

  12/22/2022

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets.

• Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

  12/22/2022

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets.

• BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

  12/22/2022

  BioNTech SE and  Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies provided approximately 11,500 doses of mRNA-based COVID-19 vaccines which arrived  on the Chinese Mainland on December 21, 2022.

• Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer

  12/22/2022

  Merck and Kelun-Biotech today announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

• BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

  12/22/2022

  BioAtla, Inc. today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 41st Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 9-12, 2023.

• Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

  12/21/2022

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab.

• ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  12/21/2022

  ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

• Zymeworks Announces Participation in Upcoming Investor Conference - December 21, 2022

  12/21/2022

  Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

• Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

  12/20/2022

  Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) and Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) today jointly announced an option grant agreement through which Vaxcyte acquired an option to access expanded rights to develop and manufacture cell-free extract, among other rights.